2023-03-27 17:16:26 ET
- Terns Pharmaceuticals press release ( NASDAQ: TERN ): Q4 GAAP EPS of -$0.29.
- cash, cash equivalents and marketable securities were $283.1 million
- Research and Development (R&D) Expenses: R&D expenses were $10.7 million and $39.6 million for the quarter and year ended December 31, 2022,
- Net Loss: Net loss was $15.8 million and $60.3 million for the quarter and year ended December 31, 2022, respectively, as compared with $14.2 million and $50.2 million for the quarter and year ended December 31, 2021,
- Common Stock and Pre-Funded Warrants: As of December 31, 2022, there were 53.7 million shares of common stock and 14.6 million pre-funded warrants issued and outstanding.
For further details see:
Terns Pharmaceuticals GAAP EPS of -$0.29